DT Midstream heads into its May 5 Q1 earnings release with a tailwind from recent analyst upgrades — but the stock is already priced near consensus, leaving the print little room for disappointment.
The most notable pre-earnings development came from Morgan Stanley, which upgraded DTM to Equal-Weight from Underweight on April 22, lifting its target from $139 to $165. Goldman Sachs and Barclays both raised targets in the same window while holding cautious ratings — Goldman kept its Sell at a revised $127, and Barclays edged to $143 this week. The direction of travel is clearly upward across the Street, but the dispersion is wide: targets range from $127 to $165, flanking the stock's current price of $147.46. Wells Fargo remains the most constructive at Overweight with a $165 target. The mean consensus of $146 now essentially matches where the stock trades, which means the upcoming print — not analyst momentum — will determine whether there is a re-rating.
The bull case rests on a $3.4 billion organic backlog, up 50%, and take-or-pay contracts that insulate cash flows from spot market swings. Bears point to $3.32 billion in debt and a heavy revenue concentration on a single counterparty, Expand Energy, compounded by geographic concentration in Haynesville and the Northeast. The dividend score ranks in the 94th percentile — a sign the market prizes 's income credentials — while EPS momentum sits in just the 27th-30th percentile, reflecting little expectations-beating momentum heading into the quarter. The EV/EBITDA multiple has expanded roughly 4% over the past month to around 14.9x, tracking the stock's 9.5% one-month rally.
Short positioning offers no meaningful signal here. Short interest is a modest 3.5% of free float, down about 3% over the past month even as it ticked up slightly in recent days. Borrow costs are minimal at 0.48%, and lending availability is loose — there is no short-squeeze dynamic in play. Options positioning is mildly elevated: the put/call ratio of 0.076 is above its 20-day average of 0.043 and running at roughly 1.6 standard deviations above that mean, though the absolute level remains low. The stock gained 9.5% over the past week, broadly in line with midstream peers — WMB added 6.5%, TRGP rose 8.4%, and TRP climbed 9.2% — suggesting sector tailwinds rather than stock-specific momentum drove the move.
The May 5 print will test whether the backlog expansion and contract-backed cash flows are translating into EBITDA growth that justifies a stock trading at the top of analyst consensus, with leverage still a watchpoint for those not yet convinced the balance sheet trajectory has turned.
See the live data behind this article on ORTEX.
Open DTM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
